Abstract
DNA methylation is the best-studied epigenetic modification, and in mammals it describes the conversion of cytosine to 5-methylcytosine in the context of CpG dinucleotides. In recent years, it has become evident that epigenetic mechanisms are severely disrupted in human neoplasia, and evidence suggests that alterations of DNA methylation patterns may be an integral mechanism in the etiology of other diseases such as bipolar disorder and schizophrenia. The main effect of altered DNA methylation is the disruption of normal patterns of gene expression through genomic instability and hypermethylation of CpG islands, which together could lead to uncontrolled cell proliferation. DNA methylation can be reversed through pharmacological intervention via the systemic administration of DNA methylation inhibitors. Thus, the ability to accurately quantify DNA methylation levels in genomic sequences is a prerequisite to assess not only treatment efficacy, but also the effect of the DNA methylation inhibitors on bystander tissues. Several methods are currently available for the analysis of DNA methylation. Nonetheless, accurate and reproducible quantification of DNA methylation remains challenging. Here, we describe Bio-COBRA, a modified protocol for combined bisulfite restriction analysis (COBRA) that incorporates an electrophoresis step in microfluidics chips. Microfluidics technology involves the handling of small amounts of liquid in miniaturized systems. Bio-COBRA provides a platform for the rapid and quantitative assessment of DNA methylation patterns in large sample sets. Its sensitivity and reproducibility also make it an excellent tool for the analysis of DNA methylation in clinical samples.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jones, P. A., Laird, P. W. (1999) Cancer epigenetics comes of age. Nat Genet 21, 163–167.
Jones, P. A., Baylin, S. B. (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415–428.
Clark, S. J., Harrison, J., Frommer, M. (1995) CpNpG methylation in mammalian cells. Nat Genet 10, 20–27.
Franchina, M., Kay, P. H. (2000) Evidence that cytosine residues within 5′-CCTGG-3′ pentanucleotides can be methylated in human DNA independently of the methylating system that modifies 5′-CG-3′ dinucleotides. DNA Cell Biol 19, 521–526.
Jabbari, K., Bernardi, G. (2004) Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene 333, 143–149.
Gardiner-Garden, M., Frommer, M. (1987) CpG islands in vertebrate genomes. J Mol Biol 196, 261–282.
Larsen, F., Gundersen, G., Lopez, R., et al. (1992) CpG islands as gene markers in the human genome. Genomics 13, 1095–1107.
Szyf, M., Pakneshan, P., Rabbani, S. A. (2004) DNA demethylation and cancer: therapeutic implications. Cancer Lett 211, 133–143.
Baylin, S. B., Herman, J. G., Graff, J. R., et al. (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141–196.
Bastian, P. J., Palapattu, G. S., Lin, X., et al. (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11, 4037–4043.
Friedrich, M. G., Chandrasoma, S., Siegmund, K. D., et al. (2005) Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 41, 2769–2778.
Levenson, V. V. (2004) DNA methylation biomarkers of cancer: moving toward clinical application. Pharmacogenomics 5, 699–707.
Brock, M. V., Gou, M., Akiyama, Y., et al. (2003) Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9, 2912–2919.
Usadel, H., Brabender, J., Danenberg, K. D., et al. (2002) Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62, 371–375.
Maruyama, R., Toyooka, S., Toyooka, K. O., et al. (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61, 8659–8663.
Maruyama, R., Toyooka, S., Toyooka, K. O., et al. (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8, 514–519.
Fraga, M. F., Ballestar, E., Paz, M. F., et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102, 10604–10609.
Li, L. C., Dahiya, R. (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427–1431.
Tusnady, G. E., Simon, I., Varadi, A., et al. (2005) BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Res 33, e9.
Brena, R. M., Huang, T. H., Plass, C. (2006) Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med 84, 1–13.
Brena, R. M., Auer, H., Kornacker, K., et al. (2006) Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform. Nucleic Acids Res 34, e17.
Acknowledgements
We would like to thank Herbert Auer and Dr. Karl Kornacker, both of whom were involved in the development and testing of this protocol.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Brena, R.M., Plass, C. (2009). Bio-COBRA: Absolute Quantification of DNA Methylation in Electrofluidics Chips. In: Tost, J. (eds) DNA Methylation. Methods in Molecular Biology, vol 507. Humana Press. https://doi.org/10.1007/978-1-59745-522-0_19
Download citation
DOI: https://doi.org/10.1007/978-1-59745-522-0_19
Publisher Name: Humana Press
Print ISBN: 978-1-934115-61-9
Online ISBN: 978-1-59745-522-0
eBook Packages: Springer Protocols